Business Wire

Sard Verbinnen & Co Acquires UK Strategic Communications and Public Affairs Firm, Oakhill Communications

Share

Sard Verbinnen & Co (“SVC”), a leading global strategic communications consultancy, today announced it has acquired the UK based communications and public affairs firm, Oakhill Communications (“Oakhill”). Oakhill provides public affairs and crisis communications advice to FTSE 100 companies, corporates in Europe and around the world, high net worth individuals, leading UK non-profits and trade groups. It adds significantly to SVC’s growing capabilities in the UK and Europe. Led by founders Craig Leviton and Lee Petar, the Oakhill team will co-locate in SVC’s existing London office and fully integrate into the SVC Public Affairs practice.

“Throughout their 20-plus year careers in public affairs and communications, Craig and Lee have distinguished themselves with intelligent counsel, deep relationships with clients, and the ability to execute on complex assignments,” said SVC Co-Founders and Co-CEOs George Sard and Paul Verbinnen. “We welcome them and the entire Oakhill team to SVC.”

Sard and Verbinnen continued, “Oakhill is a natural expansion of our integrated public affairs practice, which is increasingly critical to achieving our clients’ objectives around the world. The team adds quality as well as scale and brings a vital new dimension to our London offering and the broader firm.”

SVC Public Affairs is a fully integrated offering comprised of over 30 experienced professionals across the firm. SVC Chairman of Public Affairs Bruce Haynes said, “We are excited to continue growing the SVC Public Affairs practice and welcome Craig, Lee and their team to SVC. Craig and Lee have built a highly respected business with a great client base. They are known for their strategic thinking, government and regulatory expertise, and diligence in client service. Many of our US and Asia based clients are seeking our counsel for their operations in the UK, and likewise we have been advising UK and European based clients on their interests here. Oakhill increases our ability to provide seamless counsel and execution support to them all.”

Craig Leviton said, “SVC is one of the most respected and trusted communications consultancies in the world and will provide broader capabilities for our clients and the next phase of growth for our team. Their global public affairs team is well placed to advise clients that need to navigate the US, UK and Asian markets and wider geo-political trends.”

Lee Petar said, “Becoming part of SVC provides a first-class platform to create a leading UK public affairs business. That, coupled with SVC’s market leading expertise in providing trusted, senior level corporate counsel, will lead to growth opportunities for our team as well as for our clients. We are excited about what the future will bring.”

Jon Aarons and Charlie Chichester, Managing Directors in SVC’s London office, said, “We have known and respected Craig and Lee for years. They share the same qualities that are essential to SVC’s unique culture and success, and they will align seamlessly with our existing presence here. Together we will provide clients an integrated offering of strategic communications and public affairs for ongoing corporate positioning and in specific situations affecting value and reputation, including M&A, crises, litigation, activism and other special situations.”

Leviton and Petar join the SVC Public Affairs leadership team which, in addition to Haynes, includes:

  • Ambassador Miriam Sapiro, Vice Chairman of SVC Public Affairs and Co-Head of the Washington, D.C. office, former Deputy U.S. Trade Representative.
  • Trent Duffy, Vice Chairman of SVC Public Affairs and Co-Head of the Washington, D.C. office, former Deputy Assistant to the President and Deputy White House Press Secretary.
  • Michele Davis, SVC Senior Counselor, most recently Global Head of Corporate Relations and a Management Committee member at Morgan Stanley, and formerly U.S. Treasury Department Assistant Secretary for Policy and Planning.
  • Karen Boykin-Towns, SVC Senior Counselor, previously having held leadership roles in government relations, public affairs, global policy and diversity during a 22-year career with Pfizer, and currently Vice Chairman of the NAACP National Board of Directors.

Craig Leviton Background

Craig Leviton has over 25 years’ experience in public affairs and corporate communications and has advised a wide range of clients from global firms to leading UK PLCs. Craig is a trusted adviser to CEOs and Board Chairs and has advised clients on some of the most high-profile issues in British politics in recent years on matters from Brexit and political risk to regulatory inquiries.

Craig first worked in Parliament as an adviser between 1993 and 1996. In 1998, he joined LLM Communications, a new public affairs consultancy which grew to become one of the largest public affairs consultancies in the UK.

Craig became Managing Director in 2003 and two years later oversaw the sale of LLM to Financial Dynamics. He then became the Managing Director of the Financial Dynamics Public Affairs practice.

In 2007, Craig was appointed Director of Corporate Affairs at the Gala Coral Group, one of the largest private companies in the UK. Craig sat on the Executive Committee and was responsible for the Group’s communications, Government Relations and CSR strategy.

At the end of 2009, Craig set up Heathcroft Communications, a public affairs and communications consultancy. Craig sold Heathcroft to Teneo in February 2013. In September 2015, Craig left Teneo and jointly established Oakhill Communications.

Lee Petar Background

Lee Petar has over 20 years’ experience advising Governments, FTSE 100 corporations, high net worth individuals and industry wide campaigns on communications. A veteran leader at some of the best-known PR companies in the communications industry, Lee co-founded an agency in 2007 and built the company into one of the best-known public affairs and strategic communications firms in the UK. Today Lee serves as a market leading adviser in the fields of litigation communications, the professional services sector, public interest campaigns and corporate reputation issues. He is known for advising on issues that require a complex and multi-disciplinary approach.

Lee started his career at LSA, before working at BSMG and Weber Shandwick. In 2001, he was the founding director of a newly created political and media organization dealing with high stakes, international relations issues. He joined Good Relations in 2005. He co-founded Tetra Strategy in 2007 and led its growth over the next eight years. He spearheaded some of the agency’s most complex assignments including its international work advising Governments and high-profile individuals and advising industry across sectors at a senior level. In September 2015, Lee jointly established Oakhill Communications.

About Sard Verbinnen & Co. (“SVC”)

SVC is an independent strategic communications firm focused on supporting companies through complex, high stakes situations affecting reputation and value, including transactions, proxy contests, IPOs, litigation and crises. Headquartered in New York, SVC has offices in Washington, D.C., Boston, Chicago, Houston, San Francisco, Los Angeles, London and Hong Kong. The firm has over 200 employees, including more than 20 partners. SVC has been widely recognized for its leadership in its focus areas. In 2019, Mergermarket ranked SVC the #1 Global PR Firm by deal count and value for the third consecutive year. The Holmes Report named SVC 2018 Financial PR Agency of the Year, and SVC is ranked by Chambers and Partners as a Band-1 PR Firm. For more information, please visit www.sardverb.com.

About Oakhill Communications. (“Oakhill”)

Oakhill Communications is an independent public affairs and strategic communications consultancy. Oakhill’s partners and consultants bring a wealth of experience across all aspects of strategic and crisis communications and public affairs. The Oakhill Communications team has provided senior counsel to governments, FTSE 100 companies, high profile individuals and industry bodies. Often operating as a close extension of their clients’ operations, Oakhill provides tailored advice and support that helps clients effectively negotiate and manage issues and pursue critical objectives.

Contact information

Bruce Haynes
+1 202 318 3800
Jon Aarons/Charlie Chichester
+44 20 7467 1050
svcannouncements@sardverb.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom